Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China Lifts Import Duties On Human Immunoglobulin And Vaccine

This article was originally published in PharmAsia News

Executive Summary

China's Ministry of Finance announced that the current 3 percent import duties on antiserum, human vaccines, cultured microorganisms (excluding yeast) and four types of related immunoglobulins is now lifted effective June 1 through Dec. 31. Even though the adjustment will reduce import costs, analysts see limited impact because local enterprises dominate the domestic vaccine business, while the low-priced immunoglobulin market will not attract MNCs. Many industry experts believe the policy mainly aims to meet the demands of the recent earthquake relief. However, according to the China Chamber of Commerce of Medicines & Health Products Importers & Exporters, the government's original intention is to alleviate the supply-demand conflict of products caused by a rising consumer price index. (Click here for more - Chinese Language)
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC068919

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel